Monitoring to the Evolution of Motor Function in SMA Type II Adults Patients Treated With SPINRAZA®
study id #: NCT04159987
condition: Spinal Muscular Atrophy
status: Not yet recruiting
purpose:SPINRAZA® (Nusinersen) is the first intrathecal administered drug which was approved by the FDA to treat SMA children and adults (2016). The aim is to monitor the evolution of the Motor Function Measure-32 for SMA type II adult patients treated with SPINRAZA® (Nusinersen).
intervention: Spinraza intrathecal injection
results: https://clinicaltrials.gov/ct2/show/results/NCT04159987
last updated: February 04, 2022
-
Emma Ciafaloni, MDDr. Ciafaloni is a Professor of Neurolog...
-
Jessica Nance, MD, MSDr. Jessica Nance, treats pediatric pati...
-
Patient of the Month: GiannaAfter noticing that her daughter was una...
-
Systematic Literature Review to Assess the Cost and Resource Use Associated With Spinal Muscular Atrophy ManagementSpinal muscular atrophy (SMA) is a sever...
-
George Z. Mentis, PhDGeorge Mentis received pursued B.Sc in P...
-
Safety and Efficacy of Once-Daily Risdiplam in Type 2 and Non-Ambulant Type 3 Spinal Muscular Atrophy (SUNFISH Part ...Background: Risdiplam is an oral small m...
-
Revised Upper Limb Module in Type II And III Spinal Muscular Atrophy: 24-Month ChangesThe aim of the study was to establish 24...